跳至主要内容
临床试验/NCT05168670
NCT05168670已完成不适用

Safety of Tinted Soft Scleral Eye Shields When IPL is Applied Directly on Eyelids of Subjects With Dry Eye Disease Due to Meibomian Gland Dysfunction

Lumenis Be Ltd.2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年12月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
2
主要终点
Ophthalmic morphological changes at 1 week after intervention

研究概览

简要总结

The purpose of this study is to verify the safety of tinted soft scleral eye shields when IPL is applied directly on eyelids.

详细描述

Patients with dry eye disease due to meibomian gland dysfunction will be treated with one session of IPL applied directly on upper and lower eyelids, when eyes are protected with tinted soft scleral eye shields which prevent IPL from penetrating into ocular structures. Ocular structures will be examined with various tests (including: biomicroscopy, OCT and specular microscopy) at baseline and at 10 minutes after IPL, 24 hours after IPL, and 7 days after IPL. In addition, visual acuity will be measured at each of these times, and the patient will report of any visual symptoms at each of these times. The primary objective is to verify that no morphological or functional changes occur between the baseline and the 7 days follow-up visit.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is able to read, understand and sign an IC form
  • 22 or older
  • Self-assessed symptoms are consistent with dry eye (SPEED score ≥ 10)
  • Signs of MGD, as detected in biomicroscopy
  • Fitzpatrick skin type I-V
  • Subject is willing to comply with all study procedures, including return to the clinic 1 day and 1 week after the first and only treatment within the scope of the study

排除标准

  • • Fitzpatrick skin type VI
  • Ocular surgery or eyelid surgery, within 3 months prior to screening
  • Recent ocular trauma, within 3 months prior to screening
  • Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area
  • Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface
  • Uncontrolled infections or uncontrolled immunosuppressive diseases
  • Subjects with ocular infections requiring the use of antibiotic treatment, within 3 months prior to screening
  • Legally blind in either eye
  • Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., keratoconus, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, prior chemical burn)
  • Eyelid abnormalities that affect lid function in either eye, including: entropion, ectropion, tumor, blepharospasm, lagophthalmos, severe trichiasis, and severe ptosis
  • Prior history of cold sores or rashes in the perioral area or in the planned treatment area that could be stimulated by light at a wavelength of 560 nm to 1200 nm, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus, and porphyria
  • Within 3 months prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort
  • Over exposure to sun, within 4 weeks prior to screening
  • Moderate to severely compromised corneal health as assessed by corneal fluorescein staining
  • Trans-illumination defects
  • Anisocoria or pupil deformation
  • Anterior chamber inflammation
  • Media opacities (cataract, posterior capsule opacification, corneal edema, etc.) that preclude clear visualization of the anterior segment and retina
  • Any condition revealed whereby the investigator deems the subject inappropriate for this study

结局指标

主要结局

Ophthalmic morphological changes at 1 week after intervention

时间窗: 1 week

Opinion of the study investigator (yes/no) whether there was any change in ocular structures at 1 week after intervention (based on a series of tests including biomicroscopy, corneal fluorescein staining, anterior segment OCT, posterior segment OCT, and specular microscopy)

次要结局

  • Ophthalmic morphological changes at 10 minutes after intervention(10 minutes)
  • Subjective functional change at 1 day after intervention(1 day)
  • Objective functional change at 10 minutes after intervention(10 minutes)
  • Objective functional change at 1 week after intervention(1 week)
  • Subjective functional change at 10 minutes after intervention(10 minutes)
  • Ophthalmic morphological changes at 24 hours after intervention(24 hours)
  • Objective functional change at 24 hours after intervention(24 hours)
  • Subjective functional change at 1 week after intervention(1 week)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验